IHH Healthcare – Gleneagles Global Hospitals, Partners with Bharat Biotech to Take Vaccination Penetration into Corporate Hubs & Housing Societies

Chennai, 4 May 2021: To increase the pace of immunization amid a rise in Covid cases across the country, IHH Healthcare, the leading premium healthcare provider (operating in the home markets of India, Malaysia, Singapore, Turkey), announces Gleneagles Global Hospitals partnership with Hyderabad-based Bharat Biotech (Makers of COVAXIN) to provide Covid-19 vaccines to 18-44 years. Three of the IHH Healthcare institutions in India (i) BGS Gleneagles Global Hospitals, Kengeri, Bengaluru ii) Gleneagles Global Health City, Chennai and iii) Gleneagles Global Hospitals, Lakdi-ka-pul, Hyderabad, will foray into this initiative and also widen the vaccination drive for the younger population. The vaccination drive will extend to other hospitals within the network later in the month.

This partnership comes at the backdrop of the Government of India’s announcement of a liberalised and accelerated Phase 3 Strategy of Covid-19 Vaccination from 1st May. With total commitment to fighting against the pandemic, IHH Healthcare stays as part of the accelerated drive in making the vaccination available through our hospitals, special set up at corporates and residential societies.

With the rise in the number of cases, vaccination is the need of the hour, and this initiative would help people get better and safe access to it. The partnership between Gleneagles Global Hospitals & Bharat Biotech is a focused approach to serve communities across Bangalore, Chennai, Hyderabad, and the rest of the cities within the network of hospitals.

“In these critical times, it is our responsibility and commitment to be an active part of the accelerated immunization drive to break the chain. Phase 3 would see the young adults and a majority of the working population getting covered. Apart from the vaccination drive at our hospitals, our focus is also to include larger communities through our Corporate Vaccination Program and camps at Residential Complexes. To reiterate – even after the vaccination, it is important to follow all COIVD related safety measures and protocols. We have pride in partnering with an Indian company, Bharat Biotech, which has shown commitment to innovation and development of an indigenous vaccine that is highly effective across multiple strains. “ICMR study shows that Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain. The study also demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant” stated Shriram Vijayakumar, CEO IHH Healthcare India.

IHH Healthcare India – Gleneagles Global Hospitals will continue to provide COVID vaccine to people in the age group of 45+ through the government-subsidized vaccination scheme. In addition, the hospitals are not only treating a volume of critical Covid patients but also continuing to perform numerous complex lifesaving transplants and emergency surgeries.